GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (SZSE:002399) » Definitions » COGS-to-Revenue

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) COGS-to-Revenue : 0.66 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co COGS-to-Revenue?

Shenzhen Hepalink Pharmaceutical Group Co's Cost of Goods Sold for the three months ended in Mar. 2024 was ¥900 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥1,373 Mil.

Shenzhen Hepalink Pharmaceutical Group Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.66.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Shenzhen Hepalink Pharmaceutical Group Co's Gross Margin % for the three months ended in Mar. 2024 was 34.49%.

Shenzhen Hepalink Pharmaceutical Group Co COGS-to-Revenue Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co COGS-to-Revenue Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.61 0.68 0.67 0.67

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.64 0.71 0.67 0.66

Shenzhen Hepalink Pharmaceutical Group Co COGS-to-Revenue Calculation

Shenzhen Hepalink Pharmaceutical Group Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=3645.269 / 5445.572
=0.67

Shenzhen Hepalink Pharmaceutical Group Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=899.55 / 1373.252
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Hepalink Pharmaceutical Group Co  (SZSE:002399) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Shenzhen Hepalink Pharmaceutical Group Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 899.55 / 1373.252
=34.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Shenzhen Hepalink Pharmaceutical Group Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (SZSE:002399) » Definitions » COGS-to-Revenue
Comparable Companies
SZSE:300363 SZSE:301015 SZSE:002773 SHSE:600422 SZSE:002317 SZSE:002675 SHSE:600062 SZSE:300199 SHSE:688192 SZSE:002737 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
09989:Hong Kong
Address
No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Website
https://www.hepalink.com
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Headlines

No Headlines